Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2020

View Archived Issues

Novartis presents updated results from phase III COMBI-I study

First-in-human data show safety and early hemostatic efficacy of BAY-2599023

D6PV, a novel dual apoC-II mimetic peptide that lowers plasma triglycerides in vivo

Sumitomo Dainippon Pharma describes new Nav1.1 channel activators

Boehringer Ingelheim patents GABA(A) receptor subunits alpha5beta3gamma2 negative modulators

Thrombosis leads to early termination of phase II BAY-1093884 trial

Lentiviral IFN-alpha improves survival in mouse bladder cancer models

2019-nCoV more similar to bat than human SARS

CD47 knockout improves antitumor vaccine

Myelin is deregulated in autism spectrum disorder

Immunomic Therapeutics describes EBNA1-encoding cancer vaccine

AMT-060 gene therapy provides long-term factor IX activity in hemophilia B patients

Adverum reports new interim data from phase I trial of gene therapy ADVM-022 in wet AMD

Aerpio presents further phase Ib data on ocular formulation of AKB-9778

KSQ identifies novel target for development of eTIL therapies for refractory solid tumors

Gantenerumab arm of DIAN-TU study did not meet primary endpoint

New aflibercept 8 mg formulation to enter phase III trials for DME and wet AMD

Regeneron reports 2-year data from PANORAMA study of Eylea in diabetic retinopathy

Lilly reports topline results on solanezumab from DIAN-TU study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...